$7.75
2.64% yesterday
NYSE, Jun 13, 10:00 pm CET
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Amneal Pharmaceuticals, Inc. Class A Stock News

Neutral
GlobeNewsWire
one day ago
BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third qua...
Neutral
GlobeNewsWire
15 days ago
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and Pres...
Positive
Reuters
30 days ago
Amneal Pharmaceuticals said on Thursday the U.S. Food and Drug Administration has approved its self-administered migraine drug.
Neutral
GlobeNewsWire
30 days ago
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Dr...
Neutral
GlobeNewsWire
about one month ago
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal's extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), an American biopharmaceutical company, and...
Neutral
Seeking Alpha
about one month ago
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder and Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities ...
Neutral
Business Wire
about one month ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS.
Neutral
Business Wire
2 months ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today